Solventum Corporation (SOLV)
| Market Cap | 11.71B |
| Revenue (ttm) | 8.33B |
| Net Income (ttm) | 1.56B |
| Shares Out | 173.41M |
| EPS (ttm) | 8.88 |
| PE Ratio | 7.60 |
| Forward PE | 10.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 989,755 |
| Open | 69.97 |
| Previous Close | 69.78 |
| Day's Range | 67.12 - 69.99 |
| 52-Week Range | 62.38 - 88.20 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 89.40 (+32.43%) |
| Earnings Date | May 5, 2026 |
About SOLV
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tap... [Read more]
Financial Performance
In 2025, Solventum's revenue was $8.33 billion, an increase of 0.86% compared to the previous year's $8.25 billion. Earnings were $1.56 billion, an increase of 224.84%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for SOLV stock is "Buy." The 12-month stock price target is $89.4, which is an increase of 32.43% from the latest price.
News
Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026
ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close.
Solventum Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Management outlined progress in transformation, with Separation halfway complete and full completion targeted by end of 2026. 2025 exceeded growth expectations, and 2026 guidance targets 2%-3% revenue growth and margin expansion despite tariff headwinds. Innovation and operational efficiency remain key drivers.
Solventum to Participate in the 2026 KeyBanc Healthcare Forum
ST. PAUL, Minn., March 11, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18...
Solventum beats quarterly estimates on strong demand for surgical products
Medical device maker Solventum on Thursday beat Wall Street estimates for the fourth quarter, helped by strong demand for its wound care and sterilization products.
Solventum Earnings Call Transcript: Q4 2025
Delivered strong Q4 and full-year 2025 results, with 3.3% organic sales growth and margin expansion despite headwinds from tariffs and separation costs. 2026 guidance calls for 2%-3% organic growth, margin improvement, and continued portfolio optimization, supported by new product launches and cost-saving initiatives.
Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
Reported sales decreased 3.7%; organic sales increased 3.5% Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn.
Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026
ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close.
Solventum Completes Acquisition of Acera Surgical
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S. Accelerates Solventum's business transformation through the acquisition of...
Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™ Pr...
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
ST. PAUL, Minn. , Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HI...
Solventum Transcript: Piper Sandler 37th Annual Healthcare Conference
Transformation efforts focus on active portfolio management, highlighted by the accretive Acera acquisition and ongoing restructuring programs. Growth is driven by innovation and operational efficiency, with a strong track record of execution and a commitment to further portfolio optimization.
Solventum to Participate in the 2025 Piper Sandler Healthcare Conference
ST. PAUL, Minn. , Nov. 25, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Piper Sandler Healthcare Conference on Tuesday, Dec. 2...
Solventum Announces $1 Billion Share Repurchase Program
ST. PAUL, Minn. , Nov. 20, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $...
Solventum Announces Agreement to Acquire Acera Surgical
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings, a $900 million marke...
Solventum Transcript: Stifel 2025 Healthcare Conference
Momentum continues with strong sales growth, margin expansion, and portfolio optimization, supported by specialized teams and new product launches. Full separation from 3M is on track for 2026, with restructuring and M&A readiness set to drive future growth.
Solventum Earnings Call Transcript: Q3 2025
Strong Q3 results featured 2.7% organic sales growth, margin expansion, and raised EPS guidance. Debt reduction and the P&F sale improved financial flexibility, while new initiatives and innovation drove segment outperformance.
Solventum Reports Third Quarter 2025 Financial Results
Reported sales increased 0.7%; organic sales increased 2.7% Expects full year organic sales growth to be at the high end of +2.0% to +3.0% range Increases full year adjusted earnings per share outlook...
Solventum to Participate in the 2025 Stifel Healthcare Conference
ST. PAUL, Minn. , Nov. 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, Nov. 12, 2025...
Solventum Appoints Heather Knight as Chief Commercial Officer
ST. PAUL, Minn. , Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025.
Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025
ST. PAUL, Minn. , Oct. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025, after the U.S. financial markets close.
Solventum Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
The conference highlighted accelerated transformation through the P&F divestiture, strengthening the balance sheet and enabling a shift to growth and innovation. Strategic focus includes targeted M&A, international expansion, and operational efficiency, with margin and cash flow improvements expected as separation costs decline.
Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers
ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offer...
Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers
ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tende...
Solventum Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Management outlined a multi-phase, ongoing transformation focused on culture, strategic alignment, and portfolio optimization. Recent divestitures and new product launches are driving financial improvement, with 2025–2026 EPS accretion and revenue growth expected. M&A will target tuck-in deals in core markets.
Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc.
Accelerates Solventum's business transformation to deliver long-term shareholder value Net proceeds will be used primarily to pay down debt ST. PAUL, Minn.